The transcription factor CBFB mutations indicate an improved survival in HR+/HER2- breast cancer.

CONCLUSION: This study reveals race diversity of CBFB mutation spectrum in breast cancers. CBFB mutations mainly occur in HR+/HER2- breast cancer, and it may be a promising prognostic biomarker in HR+/HER2- subgroup.
PMID: 32711101 [PubMed - as supplied by publisher]

Source: Gene - July 21, 2020 Category: Genetics & Stem Cells Authors: Guo L, Chen B, Zhang G, Wang Y, Cao L, Ren C, Wen L, Lin J, Wei G, Liao N Tags: Gene Source Type: research